{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:45:52Z","timestamp":1769064352652,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T00:00:00Z","timestamp":1561420800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T00:00:00Z","timestamp":1561420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00277-019-03738-3","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T13:08:08Z","timestamp":1561468088000},"page":"2121-2129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Predictive value of soluble interlukin-2 receptor level at diagnosis on the outcome for patients with classical Hodgkin lymphoma treated with ABVD with or without radiotherapy"],"prefix":"10.1007","volume":"98","author":[{"given":"Kento","family":"Umino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichiro","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichiro","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Toda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichi","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nagayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyomi","family":"Mashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Minakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasufumi","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Ashizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iekuni","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Ohmine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Muroi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,25]]},"reference":[{"issue":"5","key":"3738_CR1","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ajh.25071","volume":"93","author":"SM Ansell","year":"2018","unstructured":"Ansell SM (2018) Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol 93(5):704\u2013715. \n                    https:\/\/doi.org\/10.1002\/ajh.25071","journal-title":"Am J Hematol"},{"issue":"20","key":"3738_CR2","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390. \n                    https:\/\/doi.org\/10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"issue":"27","key":"3738_CR3","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","volume":"28","author":"HT Eich","year":"2010","unstructured":"Eich HT, Diehl V, Gorgen H, Pabst T, Markova J, Debus J, Ho A, Dorken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Dohner H, Borchmann P, Muller-Hermelink HK, Muller RP, Engert A (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol Off J Am Soc Clin Oncol 28(27):4199\u20134206. \n                    https:\/\/doi.org\/10.1200\/jco.2010.29.8018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9976","key":"3738_CR4","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","volume":"385","author":"K Behringer","year":"2015","unstructured":"Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann HW, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Boll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A (2015) Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin\u2019s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 385(9976):1418\u20131427. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(14)61469-0","journal-title":"Lancet"},{"issue":"21","key":"3738_CR5","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","volume":"327","author":"GP Canellos","year":"1992","unstructured":"Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA (1992) Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327(21):1478\u20131484. \n                    https:\/\/doi.org\/10.1056\/nejm199211193272102","journal-title":"N Engl J Med"},{"issue":"11","key":"3738_CR6","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1200\/JCO.2015.62.4817","volume":"34","author":"F Merli","year":"2016","unstructured":"Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, Stelitano C, Musso M, Baldini L, Galimberti S, Angrilli F, Polimeno G, Scalzulli PR, Ferrari A, Marcheselli L, Federico M (2016) Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol Off J Am Soc Clin Oncol 34(11):1175\u20131181. \n                    https:\/\/doi.org\/10.1200\/jco.2015.62.4817","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10","key":"3738_CR7","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(13)70341-3","volume":"14","author":"N Skoetz","year":"2013","unstructured":"Skoetz N, Trelle S, Rancea M, Haverkamp H, Diehl V, Engert A, Borchmann P (2013) Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin\u2019s lymphoma: a systematic review and network meta-analysis. Lancet Oncol 14(10):943\u2013952. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(13)70341-3","journal-title":"Lancet Oncol"},{"issue":"4856","key":"3738_CR8","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1126\/science.3131876","volume":"240","author":"KA Smith","year":"1988","unstructured":"Smith KA (1988) Interleukin-2: inception, impact, and implications. Science (New York, NY) 240(4856):1169\u20131176","journal-title":"Science (New York, NY)"},{"issue":"1","key":"3738_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1159\/000484711","volume":"139","author":"Y Kawaguchi","year":"2018","unstructured":"Kawaguchi Y, Nakamaki T, Abe M, Baba Y, Murai S, Watanuki M, Arai N, Fujiwara S, Kabasawa N, Tsukamoto H, Uto Y, Ariizumi H, Yanagisawa K, Hattori N, Harada H, Saito B (2018) Association of soluble interleukin-2 receptor and C-reactive protein with the efficacy of bendamustine salvage treatment for indolent lymphomas and mantle cell lymphoma. Acta Haematol 139(1):12\u201318. \n                    https:\/\/doi.org\/10.1159\/000484711","journal-title":"Acta Haematol"},{"issue":"9","key":"3738_CR10","doi-asserted-by":"publisher","first-page":"e614","DOI":"10.1038\/bcj.2017.96","volume":"7","author":"Y Kusano","year":"2017","unstructured":"Kusano Y, Yokoyama M, Terui Y, Inoue N, Takahashi A, Yamauchi H, Tsuyama N, Nishimura N, Mishima Y, Takeuchi K, Hatake K (2017) High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy. Blood Cancer J 7(9):e614. \n                    https:\/\/doi.org\/10.1038\/bcj.2017.96","journal-title":"Blood Cancer J"},{"issue":"9","key":"3738_CR11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/10245332.2017.1312204","volume":"22","author":"K Umino","year":"2017","unstructured":"Umino K, Fujiwara SI, Ikeda T, Toda Y, Ito S, Mashima K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y (2017) Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP. Hematology 22(9):521\u2013526. \n                    https:\/\/doi.org\/10.1080\/10245332.2017.1312204","journal-title":"Hematology"},{"issue":"12","key":"3738_CR12","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1080\/10428194.2016.1195498","volume":"57","author":"N Tomita","year":"2016","unstructured":"Tomita N, Suzuki T, Miyashita K, Yamamoto W, Motohashi K, Tachibana T, Takasaki H, Kawasaki R, Hagihara M, Hashimoto C, Takemura S, Koharazawa H, Yamazaki E, Taguchi J, Fujimaki K, Fujita H, Sakai R, Fujisawa S, Motomura S, Kawamoto K, Sone H, Takizawa J (2016) The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma. Leuk Lymphoma 57(12):2763\u20132770. \n                    https:\/\/doi.org\/10.1080\/10428194.2016.1195498","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"3738_CR13","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1080\/10428194.2016.1190975","volume":"58","author":"K Umino","year":"2017","unstructured":"Umino K, Fujiwara SI, Ito S, Mashima K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y (2017) Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma. Leuk Lymphoma 58(2):316\u2013323. \n                    https:\/\/doi.org\/10.1080\/10428194.2016.1190975","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"3738_CR14","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.3109\/10428194.2014.1001985","volume":"56","author":"S Shiratori","year":"2015","unstructured":"Shiratori S, Kosugi-Kanaya M, Shigematsu A, Kobayashi H, Yamamoto S, Kobayashi N, Iwasaki H, Mori A, Kunieda Y, Yutaka T, Kurosawa M, Kakinoki Y, Endo T, Kondo T, Hashino S, Teshima T (2015) Ultra-high level of serum soluble interleukin-2 receptor at diagnosis predicts poor outcome for angioimmunoblastic T-cell lymphoma. Leuk Lymphoma 56(9):2592\u20132597. \n                    https:\/\/doi.org\/10.3109\/10428194.2014.1001985","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"3738_CR15","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/annonc\/mdn677","volume":"20","author":"D Ennishi","year":"2009","unstructured":"Ennishi D, Yokoyama M, Terui Y, Asai H, Sakajiri S, Mishima Y, Takahashi S, Komatsu H, Ikeda K, Takeuchi K, Tanimoto M, Hatake K (2009) Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. Ann Oncol 20(3):526\u2013533. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdn677","journal-title":"Ann Oncol"},{"key":"3738_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2018.1504939","volume":"60","author":"K Umino","year":"2018","unstructured":"Umino K, Fujiwara SI, Minakata D, Yamamoto C, Meguro A, Matsuyama T, Sato K, Ohmine K, Izumi T, Muroi K, Kanda Y (2018) Prognostic impact of serum soluble interleukin-2 receptor level at diagnosis in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Lymphoma 60:1\u20138. \n                    https:\/\/doi.org\/10.1080\/10428194.2018.1504939","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"3738_CR17","doi-asserted-by":"publisher","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-13-1879","volume":"19","author":"PR Marri","year":"2013","unstructured":"Marri PR, Hodge LS, Maurer MJ, Ziesmer SC, Slager SL, Habermann TM, Link BK, Cerhan JR, Novak AJ, Ansell SM (2013) Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma. Clin Cancer Res 19(24):6812\u20136819. \n                    https:\/\/doi.org\/10.1158\/1078-0432.ccr-13-1879","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3738_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 25(5):579\u2013586. \n                    https:\/\/doi.org\/10.1200\/jco.2006.09.2403","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"3738_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48(3):452\u2013458. \n                    https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"3738_CR20","first-page":"57","volume":"12","author":"F Javanmardi","year":"2018","unstructured":"Javanmardi F, Saki-Malehi A, Ahmadzadeh A, Rahim F (2018) Assessing prognostic factors in Hodgkin\u2019s lymphoma: multistate illness-death model. Int J Hematol Oncol Stem Cell Res 12(1):57\u201364","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"issue":"2","key":"3738_CR21","first-page":"21","volume":"8","author":"A Ahmadzadeh","year":"2014","unstructured":"Ahmadzadeh A, Yekaninejad MS, Jalili MH, Bahadoram M, Efazat M, Seghatoleslami M, Yazdi F, Mahdipour M, Valizadeh A, Saki N (2014) Evaluating the survival rate and the secondary malignancies after treating Hodgkin\u2019s lymphoma patients with chemotherapy regimens. Int J Hematol Oncol Stem Cell Res 8(2):21\u201326","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"issue":"6","key":"3738_CR22","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1016\/j.clml.2018.04.001","volume":"18","author":"F Gaudio","year":"2018","unstructured":"Gaudio F, Pedote P, Asabella AN, Perrone T, Laddaga FE, Sindaco P, Cimmino A, D'Abbicco D, Pezzolla A, Rubini G, Specchia G (2018) Extralymphatic disease is an independent prognostic factor in Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 18(6):e261\u2013e266. \n                    https:\/\/doi.org\/10.1016\/j.clml.2018.04.001","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"3738_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/bjc.1987.83","volume":"55","author":"G Pizzolo","year":"1987","unstructured":"Pizzolo G, Chilosi M, Vinante F, Dazzi F, Lestani M, Perona G, Benedetti F, Todeschini G, Vincenzi C, Trentin L, Semenzato G (1987) Soluble interleukin-2 receptors in the serum of patients with Hodgkin\u2019s disease. Br J Cancer 55(4):427\u2013428","journal-title":"Br J Cancer"},{"issue":"4","key":"3738_CR24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illes A, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J (2018) Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med 378(4):331\u2013344. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1708984","journal-title":"N Engl J Med"},{"issue":"10114","key":"3738_CR25","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","volume":"390","author":"P Borchmann","year":"2018","unstructured":"Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Huttmann A, Dierlamm J, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kuhnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Engert A (2018) PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 390(10114):2790\u20132802. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(17)32134-7","journal-title":"Lancet"},{"issue":"11","key":"3738_CR26","first-page":"5051","volume":"32","author":"T Yamauchi","year":"2012","unstructured":"Yamauchi T, Matsuda Y, Takai M, Tasaki T, Tai K, Hosono N, Negoro E, Ikegaya S, Takagi K, Kishi S, Yoshida A, Urasaki Y, Iwasaki H, Ueda T (2012) Early relapse is associated with high serum soluble interleukin-2 receptor after the sixth cycle of R-CHOP chemotherapy in patients with advanced diffuse large B-cell lymphoma. Anticancer Res 32(11):5051\u20135057","journal-title":"Anticancer Res"},{"issue":"24","key":"3738_CR27","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","volume":"25","author":"A Gallamini","year":"2007","unstructured":"Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D'Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin\u2019s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol Off J Am Soc Clin Oncol 25(24):3746\u20133752. \n                    https:\/\/doi.org\/10.1200\/jco.2007.11.6525","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03738-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03738-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03738-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T23:12:17Z","timestamp":1592953937000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03738-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,25]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["3738"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03738-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,25]]},"assertion":[{"value":"25 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this retrospective study, formal informed consent is not required. This study was approved by the ethics committee of Jichi Medical University and performed in accordance with the Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}